| scholarly article | Q13442814 |
| P2093 | author name string | Terry G Coursey | |
| Alexander B Quiambao | |||
| Rafal A Farjo | |||
| Ronald A Wassel | |||
| P2860 | cites work | Cyclosporin nanosphere formulation for ophthalmic administration | Q57921008 |
| Effects of Sequential Artificial Tear and Cyclosporine Emulsion Therapy on Conjunctival Goblet Cell Density and Transforming Growth Factor-β2 Production | Q61851319 | ||
| Dry Eye–Induced Conjunctival Epithelial Squamous Metaplasia Is Modulated by Interferon-γ | Q61851323 | ||
| Desiccating Stress Induces T Cell-Mediated Sjogren's Syndrome-Like Lacrimal Keratoconjunctivitis | Q61851332 | ||
| Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine | Q77729873 | ||
| The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007) | Q80347907 | ||
| Topical interferon-gamma neutralization prevents conjunctival goblet cell loss in experimental murine dry eye | Q37513125 | ||
| TFOS DEWS II pathophysiology report | Q38652987 | ||
| TFOS DEWS II Epidemiology Report | Q38652994 | ||
| TFOS DEWS II Sex, Gender, and Hormones Report. | Q38652997 | ||
| TFOS DEWS II Definition and Classification Report. | Q38665717 | ||
| TFOS DEWS II pain and sensation report. | Q39453338 | ||
| TFOS DEWS II Management and Therapy Report | Q39453364 | ||
| A mouse model of keratoconjunctivitis sicca. | Q43898146 | ||
| Experimentally induced dry eye produces ocular surface inflammation and epithelial disease. | Q44339232 | ||
| Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca | Q45190856 | ||
| Utility assessment among patients with dry eye disease. | Q53379868 | ||
| Dexamethasone nanowafer as an effective therapy for dry eye disease. | Q53422132 | ||
| Neurturin-Deficient Mice Develop Dry Eye and Keratoconjunctivitis Sicca | Q28204835 | ||
| Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline | Q30818365 | ||
| Managing Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy. | Q34028408 | ||
| High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen | Q34076208 | ||
| Desiccating stress-induced chemokine expression in the epithelium is dependent on upregulation of NKG2D/RAE-1 and release of IFN-γ in experimental dry eye. | Q34476263 | ||
| Microemulsions as ocular drug delivery systems: recent developments and future challenges | Q34572807 | ||
| Veterinary ophthalmology in laboratory animal studies | Q34866382 | ||
| Chemokine receptors CCR6 and CXCR3 are necessary for CD4(+) T cell mediated ocular surface disease in experimental dry eye disease | Q35040958 | ||
| Interferon-γ exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways. | Q35221255 | ||
| Female-Specific Downregulation of Tissue Polymorphonuclear Neutrophils Drives Impaired Regulatory T Cell and Amplified Effector T Cell Responses in Autoimmune Dry Eye Disease | Q36075268 | ||
| IL-17 disrupts corneal barrier following desiccating stress. | Q36676135 | ||
| Interferon-γ-Induced Unfolded Protein Response in Conjunctival Goblet Cells as a Cause of Mucin Deficiency in Sjögren Syndrome | Q36990222 | ||
| Topical ophthalmic cyclosporine: pharmacology and clinical uses | Q37473764 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 24 | |
| P577 | publication date | 2018-09-01 | |
| P1433 | published in | Translational vision science & technology | Q27724547 |
| P1476 | title | Once-Daily Cyclosporine-A-MiDROPS for Treatment of Dry Eye Disease | |
| P478 | volume | 7 |
| Q89939043 | A Review of Topical Cyclosporine A Formulations-A Disease-Modifying Agent for Keratoconjunctivitis Sicca | cites work | P2860 |
Search more.